CN
111.png
banner
Your present location:Home/About us/News/Company/Research progress on CfDNA / Liquid biopsy

Research progress on CfDNA / Liquid biopsy

Release date:2021-11-18

Research progress on CfDNA / Liquid biopsy


Detection and characterization of lung cancer using cell-free DNA fragmentomes

Nature Communications12, Article number: 5060 (2021)

volume

Abstract

Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stageIII/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.

For details, please visit https://www.nature.com/articles/s41467-021-24994-w

Magen’s Cell-free DNA products please visit http://www.magen-tec.com/products/list.aspx?lcid=35

Back to list
Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.

This site uses cookies to improve your online experience,allow you to share content on social media,measure traffic to this website and display customised ads based on your browsing activity.